摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

D-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine

中文名称
——
中文别名
——
英文名称
D-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine
英文别名
[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2R)-2-[methyl(3-sulfanylpropanoyl)amino]propanoate
D-N<sup>2'</sup>-deacetyl-N<sup>2'</sup>-(3-mercapto-1-oxopropyl)maytansine化学式
CAS
——
化学式
C35H48ClN3O10S
mdl
——
分子量
738.299
InChiKey
ANZJBCHSOXCCRQ-GPQZUGOWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    50
  • 可旋转键数:
    8
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    158
  • 氢给体数:
    3
  • 氢受体数:
    11

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    参考文献:
    名称:
    Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancer
    摘要:
    Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human clinical trials because of unacceptable systemic toxicity. The potent cell killing ability of maytansine can be used in a targeted delivery approach for the selective destruction of cancer cells. A series of new maytansinoids, bearing a disulfide or thiol substituent were synthesized. The chain length of the ester side chain and the degree of steric hindrance on the carbon atom bearing the thiol substituent were varied. Several of these maytansinoids were found to be even more potent in vitro than maytansine. The targeted delivery of these maytansinoids, using monoclonal antibodies, resulted in a high, specific killing of the targeted cells in vitro and remarkable antitumor activity in vivo.
    DOI:
    10.1021/jm060319f
点击查看最新优质反应信息

文献信息

  • Biological materials and uses thereof
    申请人:Antikor Biopharma Limited
    公开号:US11202837B2
    公开(公告)日:2021-12-21
    The invention provides compounds comprising a therapeutic agent coupled to a carrier molecule, with a minimum coupling ratio of 5:1; wherein the carrier molecule is (i) an antibody fragment or derivative thereof or (ii) an antibody mimetic or derivative thereof; and wherein the therapeutic agents are coupled onto a lysine amino acid residue; and further wherein the therapeutic agent is not a photosensitising agent. There is also provided uses, methods relating to such compounds, as well as processes for their manufacture.
    本发明提供了由治疗剂与载体分子偶联而成的化合物,最小偶联比为5:1;其中载体分子为(i)抗体片段或其衍生物或(ii)抗体模拟物或其衍生物;治疗剂偶联在赖氨酸氨基酸残基上;以及治疗剂不是光敏剂。此外,还提供了与此类化合物有关的用途、方法及其制造工艺。
  • BIOLOGICAL MATERIALS AND USES THEREOF
    申请人:Antikor Biopharma Limited
    公开号:US20170360951A1
    公开(公告)日:2017-12-21
    The invention provides compounds comprising a therapeutic agent coupled to a carrier molecule, with a minimum coupling ratio of 5:1; wherein the carrier molecule is (i) an antibody fragment or derivative thereof or (ii) an antibody mimetic or derivative thereof; and wherein the therapeutic agents are coupled onto a lysine amino acid residue; and further wherein the therapeutic agent is not a photosensitising agent. There is also provided uses, methods relating to such compounds, as well as processes for their manufacture.
  • ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
    申请人:SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    公开号:US20190076438A1
    公开(公告)日:2019-03-14
    The present invention provides an anti-ErbB2 antibody-drug conjugate, a composition comprising the conjugate, a method for preparing the conjugate, use of the conjugate.
  • ANTI-ERBB2 ANTIBODY-DRUG CONJUGATE AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF
    申请人:SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    公开号:US20220008553A1
    公开(公告)日:2022-01-13
    Provided is a method for the prophylaxis or treatment of cancer, comprising administering to a patient in need thereof an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing, wherein A, X, Y, L, D and a are as defined herein.
  • US9056141B2
    申请人:——
    公开号:US9056141B2
    公开(公告)日:2015-06-16
查看更多